trending Market Intelligence /marketintelligence/en/news-insights/trending/1j1r58uchbrqqmml5hfc5q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

CRISPR Therapeutics chief legal officer retires

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CRISPR Therapeutics chief legal officer retires

Zug, Switzerland-based CRISPR Therapeutics AG said Tyler Dylan-Hyde retired as chief legal officer of the company.

Dylan-Hyde joined the company in January 2015.

The company develops gene-editing therapies for various diseases, including sickle cell disease and hemophilia.